Medical News

Treatment with Renin-Angiotensin System Inhibitors Improves the Prognosis of Patients with Newly Diagnosed HFpEF

Initiating renin-angiotensin system inhibitors (RASIs) in newly-diagnosed heart failure patients with preserved ejection fraction (HFpEF) improves...

12 Feb, 2019

Email this page
Beta-Blockers Improve In-Hospital Survival Post-ACS in Patients with Mid-range Ejection Fraction

A first-of-its kind study demonstrated that beta-blockers improved in-hospital survival post-acute coronary syndrome (ACS) in patients having mid-...

08 Feb, 2019

Email this page
Anemia - An Independent Risk Factor for CVD and Renal Disease in Hypertensives, despite Well-Controlled BP

Anemia, even in mildest form independently increases the risk of cardiovascular (CV) and renal events in hypertensive outpatients, despite well-...

04 Feb, 2019

Email this page
Prognostic Factors for One-Year Mortality Vary in Acute Decompensated HF Patients with and without CKD

A recent study that reaffirmed the frequent prevalence of chronic kidney (CKD) among patients with acute decompensated heart failure (HF), revealed...

01 Feb, 2019

Email this page


Date: 15th Feb 2019
Time: 7-30 pm to 9-30 pm

Key Trials

TRANSITION STUDY: Feasible and Safe to Initiate Sacubitril/Valsartan Pre-discharge in Acute HFrEF

The TRANSITION study indicates early initiation of sacubitril/valsartan pre-discharge in acute HFrEF patients is a feasible and safe option.

Impact of Sacubitril-Valsartan Treatment on Patients Hospitalized for Acute Decompensated HF

The PIONEER-HF trial ascertains the impact of sacubitril-valsartan therapy in hemodynamically stable patients hospitalized for acute decompensated...

Sacubitril/Valsartan Improves Physical and Social Activity Limitations in HFrEF Patients

Treatment with sacubitril/valsartan improves physical and social limitations in HFrEF patients in addition to the CV benefits that it provides.

Sacubitril/Valsartan vs. Enalapril in HFrEF Patients: Analyzing the Renal Impact and Associated Outcomes

The study analyzes renal effects and the associated outcomes of sacubitril/valsartan vs. enalapril in HF patients with reduced ejection fraction.  

Slide Library

Medical Management Strategy of CTEPH: Role of Riociguat

Riociguat, a stimulator of soluble guanylate cyclase, has been globally approved for the treatment of PAH and inoperable CTEPH and persistent/...

Email this page
Macitentan: 1st ERA Proven to Reduce Morbidity and Mortality in PAH

Macitentan is an orally active, potent, tissue targeting ERA that is indicated for the treatment of pulmonary arterial hypertension (PAH). It is the...

Email this page
Chronic Thromboembolic Pulmonary Hypertension

Chronic thromboembolic pulmonary hypertension (CTEPH) is the presence of mean pulmonary artery pressure (mPAP) ≥ 25 mmHg following an episode of...

Email this page
Diabetic Dyslipidemia

Dyslipidemia is one of the key risk factors for cardiovascular disease (CVD) in diabetes mellitus. This slide set provides information on the...

Email this page

Our Publications

Gutron (Midodrine hydrochloride) Monograph

Orthostatic Hypotension is common in elderly (>70 years of age) and can also occur secondary to neuropathy like in diabetes or central lesions...

Happy Hands-The Picture Says it all

Good hand hygiene, the simple task of cleaning hands at the right time and in the right way by any health care worker is essential for patient care...

Pulmonary Hypertension – An Update

This article summarises the definition, classification, pathogenesis, assessment, prognosis, diagnosis and treatment for PH.

Azmarda (Sacubitril/Valsartan) FAQs

This booklet on frequently asked questions on sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI) provides...

Patient Education

Understanding Angioplasty

Angioplasty is a life-saving procedure to open up blocked or narrowed blood vessels. This document gives a brief idea about the procedure.

Managing Your Angina

It explains the causes, risk factors, symptoms and treatment options for angina, as well as the various do’s and don’t’s in a patient-friendly...

Understanding Obesity

This document explains what is obesity, what is the impact of obesity on overall health and what are the benefits of weight loss. 


Know more about the risk factors, associated ill-effects and tips for management of hypertension or high blood pressure. 


What percent of your patients who need oral anticoagulation, receive warfarin?
27% (4 votes)
13% (2 votes)
7% (1 vote)
13% (2 votes)
33% (5 votes)
Almost all
7% (1 vote)
Total votes: 15